Business
Nuvalent Reports Pipeline Progress and Third Quarter 2021 Financial Results
ARROS-1 Clinical Trial of NVL-520 for the Treatment of Patients with Advanced ROS1-positive NSCLC and Other Solid Tumors is Open for Enrollment Company
About this update from Nuvalent, Inc.
[{"type":"text","content":"ARROS-1 Clinical Trial of NVL-520 for the Treatment of Patients with Advanced ROS1-positive NSCLC and Other Solid Tumors is Open for Enrollment\n Company On-track for Initiation of Clinical Trial of NVL-655 for the Treatment of Patients with Advanced ALK-positive NSCLC and Other Cancers in First Half of 2022\n\n\nCAMBRIDGE, Mass., Nov. 10, 2021 /PRNewswire/ -- Nuvalent, Inc., (Nasdaq: NUVL), a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today reported recent pipeline progress and third quarter 2021 financial results.\n\n \n \n \n \n \n \n\n \n\"Throughout the third quarter of 2021, we continued to progress our novel portfolio of precisely targeted therapies for patients with cancer. Notably, our first clinical trial of NVL-520, the 'ARROS-1' study, is now open for enrollment of patients with advanced ROS1-positive NSCLC and other solid tumors,\" said James Porter, Ph.D., Chief Executive Officer at Nuvalent. \"We anticipate a robust set of upcoming operational milestones, including the dosing of the first patient in our ARROS-1 study in 2021, the advancement of our parallel lead program NVL-655 into clinical development for ALK-positive cancers, and the expansion of our portfolio with additional internally developed product candidates. With a dedicated, expert team and a strong balance sheet in place, we believe we are well-positioned to achieve the milestones ahead.\" \nRecent Program Highlights\nARROS-1 Phase 1/2 Clinical Trial of NVL-520 Open for Enrollment:Nuvalent has activated multiple U.S. sites to begin enrollment in its ARROS-1 clinical trial, a Phase 1/2, multicenter, open-label, dose-escalation and expansion study evaluating NVL-520 as an oral monotherapy in patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) and other solid tumors. NVL-520 is a novel ROS1-selective inhibitor designed to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of currently available ROS1 tyrosine kinase inhibitors (TKIs). The Phase 2 portion of the ARROS-1 study is designed to support potential registration of NVL-520 in both ROS1-positive patients with NSCLC who are kinase inhibitor-naïve and who have been previously treated with ROS...